Posted by Michael Wonder on 06 Nov 2021
PHARMAC to fund baricitinib to treat moderate to severe cases of COVID-19
5 November 2021 - PHARMAC has purchased another new medicine, baricitinib, to treat moderate to severe cases of COVID-19, with 500 courses expected in New Zealand within a matter of weeks.
Baricitinib, an oral tablet, is not currently Medsafe approved for use in the treatment of COVID-19 and clinicians will need to comply with section 25 of the Medicines Act 1981.
